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Large-scale integrated cancer genome characterization efforts in-
cluding the cancer genome atlas and the cancer cell line encyclo-
pedia have created unprecedented opportunities to study cancer
biology in the context of knowing the entire catalog of genetic
alterations. A clinically important challenge is to discover cancer
subtypes and their molecular drivers in a comprehensive genetic
context. Curtis et al. [Nature (2012) 486(7403):346–352] has re-
cently shown that integrative clustering of copy number and gene
expression in 2,000 breast tumors reveals novel subgroups beyond
the classic expression subtypes that show distinct clinical outcomes.
To extend the scope of integrative analysis for the inclusion of
somatic mutation data by massively parallel sequencing, we pro-
pose a framework for joint modeling of discrete and continuous
variables that arise from integrated genomic, epigenomic, and
transcriptomic proﬁling. The core idea is motivated by the hypoth-
esis that diverse molecular phenotypes can be predicted by a set of
orthogonal latent variables that represent distinct molecular driv-
ers, and thus can reveal tumor subgroups of biological and clinical
importance. Using the cancer cell line encyclopedia dataset, we
demonstrate our method can accurately group cell lines by their
cell-of-origin for several cancer types, and precisely pinpoint their
known and potential cancer driver genes. Our integrative analysis
also demonstrates the power for revealing subgroups that are not
lineage-dependent, but consist of different cancer types driven by a
common genetic alteration. Application of the cancer genome atlas
colorectal cancer data reveals distinct integrated tumor subtypes,
suggesting different genetic pathways in colon cancer progression.
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A major goal of many cancer genome projects is to characterizekey genetic alterations in cancer and discover therapeutic
targets through comprehensive genomic proﬁling of the cancer
genome. The Cancer Genome Atlas (TCGA) studies have un-
veiled the genetic landscape of several cancer types by whole-ge-
nome and whole-exome sequencing, DNA copy number proﬁling,
promoter methylation proﬁling, and mRNA expression proﬁling
in a large number of tumors (1–5). Complementary to the tumor
project, the Cancer Cell Line Encyclopedia (CCLE) (6) and the
Sanger cell line project (7) has cataloged a compilation of ge-
netic and molecular data in almost 1,000 human cancer cell lines,
coupled with pharmacological proﬁles for a large panel of anti-
cancer drugs. These large-scale integrative genomic efforts have
been geared toward comprehensively cataloging individual ge-
nomic alterations, analogous to a reverse-engineering process
where thousands of individual cancer genomes are taken apart to
shed light on common biological principles. Unfortunately, cancer
genomes exhibit considerable heterogeneity with abnormalities
occurring in different genes among different individuals, posing
a great challenge to identify those genes with functional impor-
tance and therapeutic implications. Thus, there is a corresponding
need for a forward-engineering process that synthesizes and
integrates the information to extract biological principles from the
massive amount of data to provide useful insights for advancing
diagnostic, prognostic, and therapeutic strategies.
In a previous publication (8), we proposed an integrative
clustering framework called iCluster. The method was recently
used in a landmark study to predict novel breast cancer subtypes
with distinct clinical outcomes (9), and it was found that the joint
clustering of copy number and gene expression proﬁles resolved
the considerable heterogeneity of the expression-only subgroups.
Other approaches on data integration that have emerged in re-
cent years include generalized data decomposition methods (10,
11) and nonparametric Bayesian models (12). However, two
major challenges have not yet been fully addressed. First, the
existing methods are not designed to include both discrete (e.g.,
somatic mutation) and continuous variables, thus limiting the
ability to harness the full potential of large-scale integrated ge-
nomic datasets. In fact, most of the previous methods have fo-
cused on integrating only copy number and gene expression.
A second challenge that has not been fully addressed lies in
systematically distinguishing cancer genes that are reliable and
constant features of a subtype from those that are less reliable.
To address these challenges, we present a signiﬁcant enhance-
ment of the iCluster method, which we call iCluster+. The en-
hanced method can perform pattern discovery that integrates
diverse data types: binary (somatic mutation), categorical (copy
number gain, normal, loss), and continuous (gene expression)
values. In this paper, we demonstrate the power of this method for
integrating the full spectrum of cancer genomic data using the
CCLE and TCGA colorectal cancer datasets. A key aspect of the
method is to use generalized linear regression for the formulation
of a joint model, with respect to a common set of latent variables
that we propose represents distinct driving factors (molecular eti-
ology and genetic pathways). Geometrically, these latent variables
form a set of “principal” coordinates that span a lower dimensional
integrated subspace, and collectively capture the major biological
variations observed across cancer genomes. As a result, the latent
variable approach enables rigorous analysis of the integrated ge-
nomic data, as we show in this report can reveal common themes
that sort the tumors into distinct subgroups of biological and
clinical importance. To identify genomic features that contribute
most to the biological variation and thus have direct relevance for
characterizing the molecular subgroups, we apply a penalized
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likelihood approach (13) with lasso penalty terms (14, 15) to in-
duce sparsity. The lasso regression allows us to pinpoint the subset
of genomic features that have signiﬁcant weights on the latent
variables, which leads to enhanced interpretability and a more
stable estimation of the latent variables.
Results
iCluster+ Framework. iCluster+ integrates a diverse range of data
types (Fig. 1). First, we introduce some notations. Let xijt denote
the genomic variable associated with the jth (j∈ f1;⋯; ptg) ge-
nomic feature in the ith (i∈ f1;⋯; ng) sample of the tth
(t∈ f1;⋯;mg) data type. A genomic feature can be either
a protein-coding gene or non–gene-centric elements of interest
(genomic region, CpG sites, microRNA, etc.), depending on the
data type. Let zi = ðzi1;⋯; zikÞ′ be a column vector consisting of k
unobserved latent variables.
The core idea is the following. We use a set of latent variables to
represent k distinct driving factors (molecular drivers), which
predict the values of the original p=
P
tpt genomic variables, and
collectively capture the major biological variations observed across
cancer genomes. We assume zi are continuous valued variables
that represent continuous spectrums of driver activation (hence
aggressiveness of the tumor) and follow a standard multivariate
normal distribution N(0, Ik). The mean zero and identity co-
variance matrix Ik are necessary identiﬁability constraints in the
joint model we will introduce shortly. The identity covariance
matrix also has a biological motivation to allow for discovery of
orthogonal driving factors, i.e., Ik deﬁnes latent factors zk and zk′,
where k≠ k′ represent orthogonal oncogenic processes; this is
appealing because there is increasing evidence that molecular
drivers tend to be altered in mutually exclusive sets of patients,
representing distinct oncogenic mechanisms (16–18).
The genomic variables xijt ðj= 1;⋯; pt; t= 1;⋯;mÞ are con-
nected to the latent process via a parametric joint model in which
different genomic variables are correlated through zi. Consider
a simple example of the oncogene ERBB2 activated in a subgroup
of breast tumors (the ERBB2 subtype), where it is activated
through DNA ampliﬁcation and mRNA overexpression. In this
single driver gene example, zi induces correlation between the
copy number and the expression changes for ERBB2. The values
of zi can then be used to sort tumors by the degree of ERBB2
activation jointly estimated from both genomic measures. Apply-
ing the concept to a genome-wide multivariate analysis without
prior knowledge of the molecular drivers, the latent variable ap-
proach facilitates the identiﬁcation of common associations to
provide insights into the underlying driving factors responsible for
the phenotypic diversity of the tumor.
We now describe our modeling approach to this problem. In
our model, if xijt is a binary variable (e.g., mutation status), we
consider the following logistic regression:
log
P

xijt = 1
zi

1−P

xijt = 1
zi
= αjt + βjtzi;
where and Pðxijt = 1jziÞ is the probability of gene j mutated in
patient i given the value of the latent factor zi; αjt is an intercept
term; and βjt is a length-k row vector of coefﬁcients that de-
termine the weights genomic variable j contributes to the
latent variables.
If xijt is a multicategory variable (e.g., copy number states: loss/
normal/gain), we consider the following multilogit regression:
P

xijt = c
zi

=
exp

αjct + βjctzi

PC
ℓ= 1 exp

αjℓt + βjℓtzi
;  c= 1;⋯;C;
where fPðxijt = 1jziÞ;⋯;Pðxijt =CjziÞg denote the probability of the
states of the categorical variable (e.g., copy number loss, normal,
gain) given the value of zi; αjct is the intercept term; βjct is a length-k
row vector of regression coefﬁcients for category c; and C is the
total number of categories. This parametrization is not estimable
without constraints. The L1 regularization we will introduce shortly
deals with this parameter ambiguity in a natural way (13).
If xijt is a continuous variable, we assume it follows a normal
distribution and consider the standard linear regression
xijt = αjt + βjtzi + «ijt; «ijt ∼N

0; σ2jt

;
where the error terms are uncorrelated, and σ2jt is the residual
variance not accounted for by the common associations represented
by zis. Finally, if xijt is a count variable (sequencing data), we con-
sider the following Poisson regression:
log

λ

xijt
zi

= αjt + βjtzi;
where λðxijtjziÞ is the conditional mean of the count given zi.
To identify the genomic variables (e.g., ERBB2 ampliﬁcation
and overexpression) that make important contributions to the
latent process, a sparse coefﬁcient vector consisting of mostly
zero coefﬁcients is particularly useful. To obtain a sparse model,
we apply the lasso (L1-norm) penalty (14) and consider the fol-
lowing penalized likelihood estimation:
max
αjt;βjt
ℓ

xijt; zi; αjt; βjt

−
Xm
t= 1
Xpt
j= 1
λt
βjt

1
;
where kβjtk1 = jβj1tj+ . . . + jβjktj is the L1-norm penalty and λts are
nonnegative tuning parameters that balance the model complexity
and ﬁt. Notice the sparsity-inducing parameter λt (hence the de-
gree of sparsity) is allowed to take different values for different
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Fig. 1. Integration of diverse data types by a latent
variable approach. A simpliﬁed illustration of the
TCGA CRC subtype discovery using iCluster+, re-
vealing tumor subtypes characterized by TP53 mu-
tation, somatic hypermutation, CIN, CIMP, and chr8q
ampliﬁcation. A gene-centric analysis of the chr8q
region highlights MYC ampliﬁcation and overex-
pression. Details of the TCGA CRC subtypes are dis-
cussed in Results and in Fig. 4.
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data types. The values are determined by a model selection pro-
cess using a Bayesian information criterion (BIC). The joint log-
likelihood, however, cannot be evaluated in closed form and has
an integral with dimension equal to the length of the latent vari-
able zi. We derived a modiﬁed Monte Carlo Newton–Raphson al-
gorithm (13, 19). Details are described in SI Methods. The software
to implement the method is available at www.mskcc.org/research/
epibio/iClusterPlus.
Cancer Cell Line Encyclopedia Data Application. We ﬁrst applied
our method to the CCLE dataset (6) integrating chromosomal
copy number, gene expression, and mutation by massively
parallel sequencing in 729 human cancer cell lines representing
more than 30 tumor types. A 12-cluster solution (Fig. 2) was
selected from an extensive model-tuning process as described
in SI Methods. Brieﬂy, the number of clusters was determined
by a deviance ratio metric that can be interpreted as the per-
centage of total variation explained by the current model. The
percent explained variation typically increases as we introduce
more clusters. The optimal k was thus chosen at a transition
point beyond which the additional divisions no longer provide
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Fig. 2. Integrated clustering of 729 cancer cell lines using iCluster+ reveals 12 cell line clusters characterized by distinct mutational, copy number, and gene
expression proﬁles. (A) Heat map display of lasso-selected cluster-discriminant features. Rows are features and columns are cell line samples sorted by cluster
assignment. Within each cluster, samples are further sorted by tissue type. (Top) Genes that are mutated (black) or not mutated (white) in each cluster. (Middle)
Genomic regions ampliﬁed (red) or deleted (blue). (Bottom) Genes overexpressed (red) or underexpressed (blue) in each cluster. (B) Known and candidate
cancer genes associated with each integrated cluster, determined by gene-wise Fisher’s combined probability test to identify genes with strongly concordant
copy number and expression changes. The y axis is the χ2 = − 2ðlog  Pcn + log  PexpÞ statistic in each cluster where Pcn, Pexp denote P values for cluster-speciﬁc copy
number and expression alterations, respectively. The most signiﬁcant genes that show concordant ampliﬁcation/overexpression (red) or loss/underexpression
(blue) in the corresponding cluster are highlighted. Genes with asterisks are annotated in the cancer gene consensus. The column of color pie charts indicates
the histological composition in each integrated cluster. The most representative histologies are indicated on the right side of the pie chart.
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signiﬁcant improvement (Fig. S1). We repeated the same run
for k = 1 to 20 ﬁve times and Fig. S2 suggested that the var-
iation is small. Cluster assignment can be found in Dataset S1
and Fig. S3 shows the silhouette plot for the 12 clusters. We
used lasso penalized regression to induce sparsity and balance
the complexity and ﬁt of the model. The corresponding penalty
parameters were chosen by minimizing a BIC over an m-di-
mensional search domain. As a result, a set of 233 mutated
genes, 7,567 copy number regions, and 3,987 differentially
expressed genes were found to have signiﬁcant weights on the
latent variables, and collectively explain the majority of the
observed variation.
There is great variation in patterns of mutation, copy number
alteration, and gene expression changes across the 12 integrated
clusters (Fig. 2A). The histological composition within each in-
tegrated cluster is shown in Fig. 2B. The mutational spectrum
includes known driver genes in speciﬁc cancer types. Notably, most
RB1 mutations fall exclusively in cluster 1, which consists of pri-
marily small-cell lung cancer (SCLC) cell lines. BRAF mutations
are tightly associated with the melanoma cell lines in cluster 10.
A unique observation from the integrative clustering of mutation,
copy number, and gene expression proﬁles is that several sub-
groups are not lineage-dependent. with strong correlation to
a speciﬁc tissue of origin. Instead we observe different cancer types
converge to the same integrated cluster because they are driven by
a shared genetic alteration. For example, KRAS mutations are
most prevalent in cluster 9, which includes both non–small-cell
lung cancer (NSCLC) and pancreatic cancer cell lines. Addition-
ally, cluster 6 (large intestine and endometrial) displays a hyper-
mutated phenotype that has been well characterized in both colon
and endometrial cancers with DNA repair deﬁciency. We also
observe similar convergence of cancer cell lines of different cell of
origins to the same integrated clusters driven by copy number and
gene expression, indicating the potential of identifying common
drivers cross cancer types in an integrated pan-cancer analysis.
We performed a gene-centric integration using Fisher’s com-
bined probability test as a second-tier analysis (SI Methods) to
highlight speciﬁc genes as potential drivers that provide the se-
lective advantage of speciﬁc copy number alterations. Fig. 2B
reveals known and candidate cancer genes associated with each
integrated cluster emerged from the gene-centric integration. By
Fisher’s combined probability test, the top-ranking genes in cluster
1 that show selective copy number loss and underexpression in-
clude two tumor suppressor genes, XPC and BAP1, which have
been previously linked to lung cancer (20) and mesothelioma
(21). The hematopoietic cell lines were divided into integrated
clusters 2 and 3, which do not show distinguishable differences in
gene expression proﬁles, but are distinctly different in somatic
copy number alterations. The gene-centric integration revealed
selective ampliﬁcation and overexpression of MYB and PCM1 in
cluster 2 (predominantly acute and chronic myeloid leukemia
cell lines). Both genes have been previously implicated in a va-
riety of hematological malignancies (22–24). Our analysis also
revealed selective ampliﬁcation and overexpression of MITF in
cluster 10, previously identiﬁed as a lineage survival oncogene in
melanoma (25). Similar results forMITF were observed from our
integrated clustering analysis of the NCI60 dataset (Figs. S4 and
S5). In addition to these ﬁndings, many known cancer drivers,
including ERBB2 in breast cancer cell lines (cluster 4), EGFR
and MET ampliﬁcation and overexpression in lung adenocarci-
noma (cluster 8), andMYCN ampliﬁcation and overexpression in
cluster 7, which is enriched for neural tumor cell lines, can be
correctly identiﬁed (Fig. 2B).
Nevertheless, the full potential of our ﬁndings lies in those
cluster-speciﬁc genes that show strong evidence of concordant
alterations, and yet have not been linked to the particular cancer
type based on the existing knowledge. For example, the gene-
centric integration of SCLC-enriched cluster 1 identiﬁed
concordant loss and underexpression of SHISA5 (Scotin), a p53-
inducible ER stress protein (26), and concordant ampliﬁcation
and overexpression of gastrin-releasing peptide (GRP; Fisher’s
combined probability test P = 10−65 and P = 10−87 respectively).
Based on our results, we propose that these two genes are likely
driver genes for SCLC. The full lists of known (27) and candidate
cancer genes discovered by our method that characterize each
cluster can be found in Dataset S2. Overall, the genome-wide
gene-centric integration in Fig. 2B reveals that the impact of
DNA copy number alterations on mRNA expression can be ei-
ther focal, affecting a few genes (e.g., EGFR andMET on chr7 in
cluster 8), or broad, affecting hundreds of genes (e.g., chr3, chr5,
chr10 loss in cluster 1). Functional annotation analysis of the
differentially expressed genes using DAVID (28) revealed tissue-
speciﬁc biological processes, including lymphocyte differentia-
tion in clusters 2 and 3, mammary gland development in cluster
4, and neuron differentiation in cluster 7.
We next investigated if the integrated cell lines’ clusters differed
in the sensitivity to 24 different cancer drugs. We used the “activity
area” under the dose–response curve that simultaneously captures
the efﬁcacy and potency of a drug (6). For several compounds,
including the microtubule inhibitor paclitaxel, the HDAC in-
hibitor panobinostat, and the TOP2 inhibitor topotecan, higher
sensitivity was observed for hematopoietic cell lines in integrated
clusters 2 and 3 (Fig. 3 A–C). Most notably, cluster 2 (but not
cluster 3) cell lines showed selective sensitivity to two MEK
inhibitors, AZD6244 and PD-0325901 (Fig. 3 D and E), suggesting
a potentially clinically important ﬁnding that a subgroup of he-
matological malignancies may respond better to MEK inhibitors.
Clusters 6 and 10 also showed elevated sensitivity to the MEK
inhibitors likely driven by the activating BRAF mutation in these
cell lines (Fig. 2A). The complete response proﬁles to all of the 24
anticancer drugs are included in Fig. S6.
The Cancer Genome Atlas Colorectal Cancer Data Application. In the
most recent TCGA publication (3), genome-scale analyses of 276
colorectal carcinoma (CRC) samples were conducted, and in-
cluded analysis of exome sequence, DNA copy number, pro-
moter methylation, and mRNA expression. Based on the whole-
exome sequencing data, 16% (n = 30) of CRCs were designated
as hypermutated. Classiﬁcation based on mutation rate was then
manually compared with microsatellite instability (MSI) status,
somatic copy number alterations, CpG island methylation phe-
notype (CIMP) classiﬁcation, and gene expression proﬁles.
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Fig. 3. (A–E) Integrated clusters show differences in drug response. The
integrated cluster ID is the same as those assigned in Fig. 2.
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In this study, we performed an integrative classiﬁcation using
iCluster+ of a subset of 189 tumors that had all four data types
available. A three-cluster solution emerged. A subsampling anal-
ysis was also conducted to assess the clustering stability (SI
Methods). Fig. S7 shows cluster assignments of any random sub-
samples of the CRC dataset are on average 90% concordant.
A set of 47 mutated genes, 1,666 copy number regions, 670 CpG
sites, and 519 differentially expressed genes had nonzero weights
on the latent variables. Fig. S8 reveals distinct patterns of alter-
ations in each cluster. By ﬁner-scale ordering, applying hierar-
chical clustering of the latent variables, cluster 2 tumors further
separated into two subgroups, which we call 2a and 2b (Fig. 4;
Fig. S9). Cluster assignment can be found in Dataset S3.
The majority of subclass 2a tumors correspond to the hyper-
mutated class previously described in ref. 3, which shows a sub-
stantially higher mutational burden. These tumors are associated
with MSI, CpG island methylator phenotype (CIMP-high), as
deﬁned in ref. 3, and BRAFmutation. Furthermore, tumors in this
class have distinctly few TP53 mutations (P = 10−8) and are
chromosomally stable. Notably, among the hypermutation/MSI/
CIMP-negative tumors, our method revealed three subgroups (2b,
1, and 3) that have not been previously observed in colorectal
cancer. Speciﬁcally, cluster 2b has a low prevalence of TP53 mu-
tation and displays a low degree of chromosomal instability (CIN-
low) that is clearly different from the classic CIN phenotype as
exempliﬁed by clusters 1 and 3. To quantify the degree of somatic
copy number alterations in each subtype, we calculated the frac-
tion of the genome altered based on the number of alterations
with a log2 ratio greater than 0.2 or below −0.2 (Fig. S10). Cluster
2a tumors (CIN-negative) have the lowest degree of alteration
with an average of 3% of the genome altered. Cluster 2b tumors
(CIN-low) show a moderate degree of alteration, averaging at
14% of the genome altered. Clusters 1 and 3 tumors (classic CIN)
have the highest degree of alterations with an average of over 26%
of the genome altered. The differences are highly signiﬁcant (P <
10−15), and no signiﬁcant differences in tumor purity as measured
by the ABSOLUTE algorithm (29) were observed (P = 0.13).
Association with clinical variables reveal that class 2b has the
fewest high-stage tumors (P = 0.0001) of all of the colon cancer
subtypes, which implicates 2b as a subtype that may not need
aggressive treatment outside of surgery. Among the TP53-mu-
tated/CIN-high group, patient samples were divided by chr8q
ampliﬁcation status. In particular, cluster 1 is clearly distinguished
by chr8q ampliﬁcation.
In the gene-centric integration using Fisher’s method to identity
concordant copy number and gene expression events in cluster
1 tumors (PTDSS1, MYC, COX6C, EXT1, and RECQL4) associ-
ated with chr8q gain showed strong evidence of copy number-in-
duced gene expression. A full list of genes with concordant events
ranked by Fisher’s combined P values can be found in Dataset S4.
Cluster 3 tumors, by contrast, are chr8q normal.
Discussion
The rapidly increasing size of integrated genomic datasets cre-
ates an unprecedented opportunity to study cancer biology and
discover biomarkers and therapeutic targets in a novel way. In
this paper, we presented a hypothesis-driven model-based ap-
proach for integrative clustering. A key aspect to our approach is
the introduction of latent variables that we hypothesize to rep-
resent the spectrum of the underlying disease-driving factors,
and that these latent variables facilitate the discovery of bi-
ological properties that lead to the phenotypic diversity observed
with different cancer genomes. A great challenge of data in-
tegration that we directly addressed in this study was the dispa-
rate nature of the types of genomic variables involved. In the
integrative context, it is unsuitable to interpret the variation of
a binary variable (mutation status) in the same way as the vari-
ation of a continuous variable would be interpreted. Different
modeling assumptions need to be considered. The methodolog-
ical basis of iCluster+ thus combines a diverse range of gener-
alized linear models to address this challenge. In our framework,
mutations are modeled as a multivariate binomial process. Cat-
egorical observations are modeled as multivariate multinomial
random variables. Count data are modeled as multivariate Poisson
variables, and continuous measures such as gene expression are
modeled as multivariate normal. Given the proper distributional
assumptions for these diverse types of genomic variables, we ﬁt
simultaneous generalized linear regression of the diverse types of
genomic variables with respect to a common set of latent variables
representing distinct sets of molecular drivers.
Using two datasets, CCLE and TCGA CRC, we demonstrated
that iCluster+ is a highly effective statistical framework to extract
novel biological information from integrated cancer genomic data
for tumor classiﬁcation and cancer gene identiﬁcation. In the pan-
cancer analysis of 729 cancer cell lines representing 23 tumor
types, our method provided a comprehensive view of genetic
alterations that are speciﬁc to a cancer type, or shared by more
than one cancer type. A gene-centric integration in each cluster
accurately identiﬁed known drivers in several cancer types, in-
cluding MITF in melanoma; ERBB2 in breast cancer; EGFR and
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Fig. 4. Integrated clustering of 189 TCGA colorectal cancer samples using
iCluster+ reveals four distinct genomic subtypes (1, 2a, 2b, and 3). (Top)
Sample annotations of MSI-H, CIMP-H, mutator phenotype associated with
deﬁcient DNA damage repair (hypermutated), and BRAF and TP53 mutation
status. (Middle) Lasso-selected cluster-discriminant genes that have distinctly
different mutational spectrums in each cluster (black, mutated; white, not
mutated). (Bottom) Lasso-selected genomic regions with distinct patterns of
ampliﬁcation (red), normal (white), and deletion (blue).
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MET in lung adenocarcinoma; and MYCN in brain tumors. Our
ﬁndings also highlight many candidate biomarker or driver genes,
including XPC, BAP1, and Scotin in small-cell lung cancer, and
MYB and PCM1 in leukemia. Integrative clustering of the CCLE
data also reveals subgroups of cell lines that are not lineage de-
pendent, but rather converge to the same integrated cluster by
a common genetic alteration. Associating the integrated clusters
with the pharmacological proﬁles of 24 anticancer drug compounds
revealed selective sensitivity to MEK inhibitors in a subset of
hematopoietic cell lines, a potentially clinically important ﬁnding
that a subgroup of hematological malignancies may beneﬁt from
MEK inhibitors. In the TCGA colorectal tumor data set, our
method discovered two subtypes that have not been previously
described. A notable observation is that in addition to the classic
subtypes of chromosomally stable or unstable (CIN), we discov-
ered an intermediate CIN phenotype. In contrast to the classic
CIN (CIN-high) tumors, CIN-low tumors have distinctly few TP53
mutations. Purity analysis also revealed that the difference between
the CIN-high and CIN-low phenotypes cannot be explained by
tumor purity. Interestingly, this class appears to be the lowest
grade of all types of colon cancer, and may warrant less-aggressive
systemic treatment than other colon cancer subtypes. Furthermore,
among the CIN-high tumors, our method clearly delineated two
additional subtypes distinguished by chr8q ampliﬁed vs. normal.
Further research will address the different tumor dependencies
of these subgroups that can be the starting point for developing
targeted therapeutics.
In summary, we have shown that our method can extract useful
insights from the enormous volume of integrated cancer genomic
data to fully exploit the “parts” catalog of the cancer genomes as
generated by large-scale cancer genome projects. The outcome
can provide useful insights for developing targeted therapeutics
and informative biomarkers.
Methods
For model selection, we use a two-step approach. In the ﬁrst step, given k
(number of latent variables), we estimate the lasso penalty parameters
fλtgmt=1 that minimize a BIC. However, to determine the optimal combination
of the penalty parameter values, a very large search space needs to be
covered. We used an efﬁcient sampling method based on a uniform design
(30). A theoretical advantage of the uniform design over an exhaustive grid
search is the uniform space-ﬁlling property that avoids wasteful computa-
tion at nearby sampling points. In the next step, we choose the best k based
on a deviance ratio
dev:ratio=
ℓk;λ^ − ℓ0
ℓsat − ℓ0
;
where λ^= fλ^tgmt=1 are the combination of penalty parameter values that give
the minimal BIC under k, ℓ 0 is the log-likelihood under the null (intercept)
model, and ℓsat denotes the log-likelihood under the saturated model (a model
with a latent variable per sample). The deviance ratio metric can be inter-
preted as the percentage of variation explained by the current model, and k
is thus chosen to achieve an optimal value of the deviance ratio.
A limitation to the current method is that statistical inference (signiﬁcance
test and conﬁdence intervals for the “ﬁnal” model selected) is not straight-
forward due to the computational complexity and the use of penalized re-
gression. Statistical inference after model selection (post–model-selection
inference) is important yet very challenging even for simple linear re-
gression. For a recent discussion on the topic, see refs. 31 and 32. In Berk
et al. (32), an intuitive and practical strategy has been proposed, but it
fails when the dimension of the variables is high. To our knowledge, there is
no clear solution in statistics for post–model-selection inference problem for
high-dimensional data; it is an interesting problem that may warrant
future investigation.
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